Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.

ABSTRACT: BACKGROUND:Treatment of hyperphosphataemia is the primary goal of chronic kidney disease-mineral and bone disorder (CKD-MBD) management. This post hoc analysis of a randomized, Phase 3 study evaluated the effects of 1-year treatment with the phosphate binders sucroferric oxyhydroxide or sevelamer carbonate ('sevelamer') on CKD-MBD indices among dialysis patients with hyperphosphataemia. METHODS:After a 2- to 4-week washout from previous phosphate binders, 1059 patients were randomized 2:1 to sucroferric oxyhydroxide 1.0-3.0?g/day (n?=?710) or sevelamer 2.4-14.4?g/day (n?=?349) for up to 24?weeks. Eligible patients enrolled in a 28-week extension. This post hoc analysis was performed for patients who completed ?1 year of continuous treatment (n?=?549). As the treatment groups showed similar CKD-MBD outcomes, the data were pooled for this analysis. RESULTS:Phosphate-binder therapy was associated with significant and sustained 30% reductions in serum phosphorus (P?

SUBMITTER: Ketteler M 

PROVIDER: S-EPMC6603395 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature